BCI
VRNA

Brinker Capital Investments’s Verona Pharma VRNA Stock Holding History

Brinker Capital Investments’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,918
Closed -$249K – 2059
2025
Q1 		$249K Buy
+3,918
New +$234K ﹤0.01% 1711
2024
Q4 		– Sell
-12,051
Closed -$347K – 1918
2024
Q3 		$347K Sell
12,051
-1,898
-14% -$46.7K ﹤0.01% 1472
2024
Q2 		$202K Sell
13,949
-805
-5% -$11.8K ﹤0.01% 1643
2024
Q1 		$237K Sell
14,754
-2,085
-12% -$36.1K ﹤0.01% 1552
2023
Q4 		$341K Sell
16,839
-1,477
-8% -$21.8K ﹤0.01% 1360
2023
Q3 		$299K Sell
18,316
-900
-5% -$17.3K ﹤0.01% 1381
2023
Q2 		$406K Buy
19,216
+1,125
+6% +$24K ﹤0.01% 1292
2023
Q1 		$363K Buy
18,091
+6,145
+51% +$133K ﹤0.01% 1273
2022
Q4 		$312K Sell
11,946
-380
-3% -$5.06K 0.01% 1134
2022
Q3 		$126K Buy
+12,326
New +$104K ﹤0.01% 1295

Other funds holding VRNA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Brinker Capital Investments's VRNA Position: Q2 2025 in Review

Brinker Capital Investments sold out of Verona Pharma (VRNA) in Q2 2025, closing a stake of 3,918 shares — an estimated $249K sold.

Brinker Capital Investments first reported a position in VRNA in Q3 2022 and held it in 10 quarters. The position peaked at $406K in Q2 2023. 292 funds tracked by Wall St. Rank hold VRNA as of Q2 2025.

  • Brinker Capital Investments reported no remaining Verona Pharma position as of Q2 2025 after selling out during the quarter.
  • Brinker Capital Investments sold 3,918 Verona Pharma shares in Q2 2025, an estimated $249K.
  • Brinker Capital Investments first reported a position in Verona Pharma in Q3 2022 and held it in 10 quarters.
  • Brinker Capital Investments's Verona Pharma position peaked at $406K in Q2 2023.
  • 292 funds tracked by Wall St. Rank held Verona Pharma as of Q2 2025.

Based on Brinker Capital Investments's 13F filing for Q2 2025, filed 14 Aug 2025.